



## **Arena Pharmaceuticals to Present at the Granite Financial Group Healthcare Investors Conference**

SAN DIEGO, Nov 16, 2004 /PRNewswire-FirstCall via COMTEX/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that it will present a corporate update at the Granite Financial Group Healthcare Investors Conference on Thursday, November 18, 2004, at 8:30 a.m. Pacific Time (11:30 a.m. Eastern Time). Dominic P. Behan, Ph.D., Chief Scientific Officer & Senior Vice President, will give the presentation, which will be webcast live over the Internet. The conference will be held at the Del Mar Marriott in San Diego.

To access the live or archived presentation, simply log on to the following link <http://www.vcall.com/CEPage.asp?ID=89711> or [www.arenapharm.com](http://www.arenapharm.com) under the investor relations section. Please connect to either one of the websites several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary. The presentation will be archived for 30 days on both websites.

### About Arena Pharmaceuticals

Arena is a biopharmaceutical company focusing on the discovery, development and commercialization of drugs in four major therapeutic areas: metabolic, cardiovascular, inflammatory and central nervous system diseases. Arena is developing a broad pipeline of compounds that act on an important class of drug targets called G protein-coupled receptors, or GPCRs, and that are being developed using Arena's proprietary technologies, including CART™ (Constitutively Activated Receptor Technology) and Melanophore. Arena also has research collaborations with Merck, Fujisawa, Taisho and TaiGen for products in a number of different indications. For additional information about Arena, visit their website at <http://www.arenapharm.com>.

### Forward-Looking Statements

Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about Arena's strategy, technologies, preclinical and clinical programs, ability to identify and develop drugs, future achievements, goals and expectations, as well as other statements that are not historical facts. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, the timing, success and cost of Arena's research, out-licensing endeavors and clinical studies, Arena's ability to obtain additional financing, and the timing and receipt of payments and fees, if any, from Arena's collaborators. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's SEC reports, including Arena's most recent quarterly report on Form 10-Q. These forward-looking statements represent Arena's judgment as of the date of this release. Arena disclaims any intent or obligation to update these forward-looking statements.

Arena Pharmaceuticals® and Arena® are registered service marks of the company. CART™ is an unregistered service mark of the company.

For more information, please contact: Jack Lief of Arena Pharmaceuticals, +1-858-453-7200; or Susan Neath of Atkins + Associates, +1-858-527-3486, for Arena Pharmaceuticals.

SOURCE Arena Pharmaceuticals

<http://www.vcall.com/CEPage.asp?ID=89711>